2023
Changes in planned disease management after piflufolastat F18 PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study.
Pouliot F, Gorin M, Rowe S, Saperstein L, Denes B, DiPippo V, Stambler N, Morris M, Siegel B. Changes in planned disease management after piflufolastat F18 PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study. Journal Of Clinical Oncology 2023, 41: 61-61. DOI: 10.1200/jco.2023.41.6_suppl.61.Peer-Reviewed Original ResearchBaseline PSA levelsPET/CTLow PSA levelsPSA levelsTreatment recommendationsDisease managementLow baseline PSA levelsBiochemically recurrent prostate cancerPositive PET/CTBaseline PSA valuePhase 3 studySubset of patientsRecurrent prostate cancerProstate cancer patientsAvailable clinical informationConventional imaging resultsYears of ageDisease management plansManagement QuestionnaireEquivocal imagingEvaluable patientsNegative PETSystemic therapyDisease recurrenceInitial staging
2022
Piflufolastat F 18-PET/CT in patients with prostate cancer: An analysis of OSPREY (cohorts A and B) standardized uptake value (SUV) results stratified by PSA and Gleason score.
Gorin M, Rowe S, Pienta K, Carroll P, Pouliot F, Probst S, Saperstein L, Preston M, Alva A, Patnaik A, Stambler N, Siegel B, Morris M. Piflufolastat F 18-PET/CT in patients with prostate cancer: An analysis of OSPREY (cohorts A and B) standardized uptake value (SUV) results stratified by PSA and Gleason score. Journal Of Clinical Oncology 2022, 40: 5024-5024. DOI: 10.1200/jco.2022.40.16_suppl.5024.Peer-Reviewed Original ResearchHigh-risk PCaBaseline PSAGleason scoreVolume of interestAverage SUVProstate-specific membrane antigen (PSMA) PET/CTSpecific Membrane Antigen PET/CTBaseline PSA levelsGS 9PET/CTSUV resultsPelvic lymphadenectomyPSA levelsInitial stagingDisease recurrenceProspective studyBiopsy statusMetastatic PCaRadical prostatectomyCT uptakeClinical trialsProstate cancerLesion locationCentral readersNegative lesionsPiflufolastat F 18-PET/CT in prostate cancer patients: An analysis of OSPREY (Cohorts A and B) standardized uptake value (SUV) results stratified by PSA and gleason score.
Gorin M, Rowe S, Pienta K, Carroll P, Pouliot F, Probst S, Saperstein L, Preston M, Alva A, Patnaik A, Stambler N, Siegel B, Morris M. Piflufolastat F 18-PET/CT in prostate cancer patients: An analysis of OSPREY (Cohorts A and B) standardized uptake value (SUV) results stratified by PSA and gleason score. Journal Of Clinical Oncology 2022, 40: 35-35. DOI: 10.1200/jco.2022.40.6_suppl.035.Peer-Reviewed Original ResearchHigh-risk PCaBaseline PSAGleason scoreVolume of interestAverage SUVProstate-specific membrane antigen (PSMA) PET/CTSpecific Membrane Antigen PET/CTBaseline PSA levelsGS 9Prostate cancer patientsPET/CTSUV resultsPelvic lymphadenectomyPSA levelsInitial stagingDisease recurrenceProspective studyBiopsy statusCancer patientsMetastatic PCaRadical prostatectomyClinical trialsCT uptakeLesion locationCentral readers